Moderna says its messenger RNA flu vaccine candidate, mRNA-1010, successfully boosted titers against all four influenza strains it’s being tested against during an ongoing phase 1 study, even at lowest dose, and that no significant safety concerns were observed.
Source: Drug Industry Daily